Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective melanocortin receptor agonist. Research has investigated its effects on skin pigmentation via MC1R, appetite and metabolic regulation via MC4R, sexual function, and cardiovascular physiology.
Melanocortin Receptor System
The melanocortin system comprises five G protein-coupled receptors (MC1R through MC5R) with diverse distributions and functions. MC1R on melanocytes regulates pigmentation, MC2R mediates adrenal function, MC3R influences energy balance, MC4R controls appetite and sexual function, and MC5R is involved in exocrine gland secretion. MT-II's non-selectivity means it activates multiple receptor subtypes simultaneously.
Pigmentation Research
MT-II was originally developed at the University of Arizona as a potential sunless tanning agent — a way to induce skin darkening without UV radiation to reduce UV-related skin cancer risk. Research demonstrated dose-dependent increases in skin pigmentation via MC1R stimulation of eumelanin production in melanocytes.
Appetite and Metabolic Effects
MC4R plays a critical role in energy homeostasis, and MT-II's MC4R agonism produces appetite suppression as an observed effect in research settings. Loss-of-function MC4R mutations are associated with severe early-onset obesity in humans, which highlights the receptor's importance in weight regulation.
Safety Flags in Research Literature
MT-II research has identified several safety concerns that have limited its pharmaceutical development: nausea is a common side effect, cardiovascular effects including blood pressure changes have been observed, and concerns about potential stimulation of existing melanocytic nevi have been raised. Regulatory approval has not been granted in any major jurisdiction.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.